Arca
Skip to content
Tools
Tools

CD276: CD276 antigen

May participate in the regulation of T-cell-mediated immune response.

  • Drugs that act on it: 2
  • Approved: 0
  • In phases 1 to 3: 2
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on CD276, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 1
  • Other 1

Approved0

    Phase 30

      Phase 22

      • Enoblituzumab
      • 8H9 131I

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        EnoblituzumabPhase 2MacroGenicsAntibodyCross-linking agentCD276 antigen cross-linking agent2
        8H9 131IPhase 2Y-mAbs TherapeuticsOtherBinding agentCD276 antigen binding agent0

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 2 in all, from ClinicalTrials.gov.
        Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate CancerEnoblituzumabPhase 2Active, not recruitingSidney Kimmel Comprehensive Cancer Center at Johns HopkinsAug 28, 2023
        Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate CancerEnoblituzumabPhase 2Active, not recruitingSidney Kimmel Comprehensive Cancer Center at Johns HopkinsOct 4, 2016

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Response to statin0.32
        • Abnormality of the skeletal system0.29
        • Head and neck squamous cell carcinoma0.23
        • Cancer0.13
        • Non-small cell lung carcinoma0.13
        • Triple-negative breast carcinoma0.12
        • Pancreatic neoplasm0.12
        • Neoplasm0.12

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712879, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q5ZPR3, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.